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gradients of repolarization in arrhythmogenesis in Langendorff-perfused
hypokalaemic murine hearts paced from the right ventricular epicardium.
Methods: Left ventricular epicardial and endocardial monophasic action
potentials (MAPs) and arrhythmogenic tendency were compared in the
presence and absence of the L-type Ca
2+ channel blocker nifedipine (10 nm–
1 lm) and the calmodulin kinase type II inhibitor KN-93 (2 lm).
Results: All the hypokalaemic hearts studied showed prolonged epicardial
and endocardial MAPs, decreased epicardial-endocardial APD90 difference,
EADs, triggered beats and ventricular tachycardia (VT) (n ¼ 6). In all
spontaneously beating hearts, 100 (but not 10) nm nifedipine reduced both
the incidence of EADs and triggered beats from 66.9   15.7% to
28.3   8.7% and episodes of VT from 10.8   6.3% to 1.2   0.7% of
MAPs (n ¼ 6 hearts, P < 0.05); 1 lm nifedipine abolished all these phe-
nomena (n ¼ 6). In contrast programmed electrical stimulation (PES) still
triggered VT in six of six hearts with 0, 10 and 100 nm but not 1 lm nif-
edipine. 1 lm nifedipine selectively reduced epicardial (from 66.1   3.4 to
46.2   2.5 ms) but not endocardial APD90, thereby restoring DAPD90 from
)5.9   2.5 to 15.5   3.2 ms, close to normokalaemic values. KN-93 simi-
larly reduced EADs, triggered beats and VT in spontaneously beating hearts
to 29.6   8.9% and 1.7   1.1% respectively (n ¼ 6) yet permitted PES-
induced VT (n ¼ 6), in the presence of a persistently negative DAPD90.
Conclusions: These ﬁndings empirically implicate both EADs and triggered
beats alongside arrhythmogenic substrate of DAPD90 in VT pathogenesis at
the whole heart level.
Keywords arrhythmogenesis, early afterdepolarizations, hypokalaemia,
mouse heart, transmural gradients of repolarization.
Hypokalaemia is a recognized risk factor for the devel-
opment of torsade de pointes (TdP), a life threatening
form of ventricular tachycardia (VT), in which the
electrocardiographic QRS complexes appear to twist
about the isoelectric line (Antzelevitch et al., 1996;
Berthet et al. 1999). Although several different mecha-
nisms ofTdPinductionhavebeenreported, thetwomost
common theories, not necessarily exclusive, are (1)
Delayed repolarization, reﬂecting cardiac action poten-
tial duration (APD) prolongation (Gintant et al. 1991,
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to cellular depolarizations occurring in phases 2 or 3 of
repolarization, early afterdepolarizations (EADs), which
may give rise to salvos of premature action potentials,
triggered activity and subsequent episodes of VT
(Eckardt et al. 1998, Viswanathan et al. 1999). EADs
have been implicated as critical initiation factors for
arrhythmias in the congenital long QT (LQT) syndrome
(Shimizu et al. 1991), drug-induced LQT syndrome
(Aiba et al. 2005) and electrolyte abnormalities such as
hypokalaemia (Killeen et al. 2007). (2) Differential
expression of cardiac ion channel currents throughout
the thickness of the ventricular wall, establishes a
transmural gradient of APD, which may become signiﬁ-
cantly altered following cardiac action potential prolon-
gation. An alteration in the transmural gradient of APD,
and hence refractoriness is a potentially arrhythmogenic
mechanism of action (Janse and Wit, 1989).
Previous studies in isolated myocytes have thus
indicated that EADs can occur in most cardiac cell
types; this however, does not rule out the fact that
speciﬁc groups of cells may be intricately involved in the
generation of EADs. Studies of isolated myocytes or
myocardial tissue preparations may therefore lack
fundamental cell types that are necessary for the genesis
of EADs. Single cell studies have failed to clarify the
relationship between EADs at the single myocyte level
and arrhythmogenesis at the whole heart level, and the
relationship between EADs and transmural gradients
and repolarization. Additionally, the vast majority of
single cell studies did not take into consideration
important transmural differences in the patterns of ion
channel expression in the mammalian heart, choosing to
study a mixed population of both epicardial and
endocardial myocytes. The use of whole hearts permits
the examination of properties of intercellularly coupled
cells in situ, not possible in isolated cell preparations;
intercellular coupling has been demonstrated to either
suppress or facilitate EADs (Huelsing et al. 2000).
Additionally, intact heart studies enable the detection
of multi-cellular pathophysiological processes such as
cardiac arrhythmias. Finally, the use of whole hearts
enables the measurement of ventricular transmural
gradients of repolarization which play an important role
in the pathogenesis of cardiac arrhythmias (Killeen et al.
2007, Stokoe et al. 2007a,b, Thomas et al. 2007a,b).
Studies in the whole heart have the advantage of
containing all myocardial cell types whilst maintaining
intercellular coupling, and could provide more physio-
logically relevant information regarding the induction
and propagation of EADs and arrhythmias. The present
study accordingly used a recently established murine
whole heart model of arrhythmogensis (Killeen et al.
2007), which elicits prominent EADs, triggered activity
and VT in the setting of AP prolongation.
We sought to resolve the causal relationship between
two macroscopic pathophysiological phenomena, EADs
and arrhythmogenic substrate of transmural gradients
of repolarization in the genesis of arrhythmias at the
whole heart level. The two procedures used nifedipine
and KN-93 empirically as pharmacological tools with
independent targets to separate out EADs from ar-
rhyrhmogenic substrate, and to assess the contribution
of each of these phenomena to the genesis of arrhyth-
mias. In spontaneously beating hearts mid-range con-
centrations of nifedipine (100 nm) reduced EADs and
episodes of VT, but did not alter epicardial or endo-
cardial APD, preserving arrhythmogenic substrate of
DAPD90. Programmed electrical stimulation (PES)
applied premature S2 stimuli acting as surrogate EADs
and initiated VT in hearts treated with 100 nm nifedi-
pine. A higher concentration of nifedipine (1 lm)
similarly eliminated EADs and episodes of VT in
spontaneously beating hearts, but also prevented PES-
induced VT. These latter effects were accounted for by
selective abbreviation of epicardial APD, restoring
DAPD90 to control values and thus removing arrhythm-
ogenic substrate. We corroborated these ﬁndings using
KN-93, a different pharmacological agent which also
affects Ca
2+ homeostasis through distinct cellular tar-
gets compared with nifedipine. KN-93 (2 lM) reduced
EADs and episodes of VT in spontaneously beating
hypokalaemic hearts but failed to prevent PES-induced
VT. Additionally, it was shown that KN-93 did not
alter epicardial or endocardial APD and DAPD90, thus
preserving arrhythmogenic substrate.
These results demonstrate the importance of both
EADs and arrhythmogenic substrate in the initiation of
ventricular arrhythmias at the whole heart level. In the
presence of a substrate, an EAD will initiate VT.
However, if EADs are empirically suppressed through
the use of nifedipine or KN-93 in spontaneously beating
hearts, arrhythmias are not initiated. Nevertheless, if
the underlying arrhythmic substrate prevails, premature
stimuli applied during PES act as surrogate EADs and
successfully initiate VT. At the highest concentration
used, nifedipine (1 lm) suppressed all EADs and
episodes of VT in spontaneously beating hearts, and
also selectively abbreviated epicardial APD, restoring
DAPD90 to control levels, thus removing the arrhythmic
substrate. Under these conditions PES failed to induce
VT. It was thus possible to separate the occurrences or
otherwise of EADs, arrhythmic substrate and VT
through their differential sensitivities to nifedipine.
These ﬁndings show for the ﬁrst time in any mamma-
lian cardiac preparation the pharmacological separ-
ation of EADs from an arrhythmic substrate,
demonstrating the importance of both EADs and
arrhythmic substrate in the initiation of arrhythmias
at the whole heart level.
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Experimental animals
The mice used in this study were kept in an animal
house at room temperature and subjected to a consistent
12 h : 12 h light : dark cycle and fed with sterile rodent
chow, having access to water at all times. Wild-type
(WT) 129 background male and female mice aged
5–7 months were used in all experiments.
Langendorff-perfused preparation
The experiments used a Langendorff-perfused prepar-
ation that has been previously adapted for murine
hearts (Balasubramaniam et al. 2004). Brieﬂy, mice
were killed by cervical dislocation in accordance with
schedule 1 of the UK Animals (Scientiﬁc Procedures)
Act 1986. The heart was then quickly excised and
submerged in ice-cold bicarbonate-buffered Krebs–
Henseleit solution containing in mm: 119 NaCl, 25
NaHCO3, 4 KCl, 1.2 KH2PO4, 1 MgCl2, 1.8 CaCl2,1 0
glucose and 2 sodium pyruvate. The solution was
bubbled with a 95% O2–5% CO2 mixture (British
Oxygen Company, Manchester, UK). The aorta was
cannulated under the buffer surface using a 21-gauge
custom-made cannula, and was attached to the cannula
needle using a micro aneurysm clip (Harvard Appar-
atus, Edenbridge UK). The preparation was then trans-
ferred to the perfusion apparatus, to which the cannula
was attached, and perfusion commenced in a retrograde
manner via the aorta with the abovementioned bicar-
bonate-buffered Krebs–Henseleit solution. Before enter-
ing the aorta, buffer was passed through 200 lm and
5 lm ﬁlters (Milipore, Watford, UK) and warmed to
37  C by means of a water jacket and circulator
(Techne model C-85A, Cambridge, UK). Perfusion
was maintained at a constant ﬂow rate of 2 to
2.5 mL min
)1 using a peristaltic pump (Watson-Mar-
low Bredel pumps model 505S; Falmouth, Cornwall,
UK). Following the start of perfusion, healthy, experi-
mentally viable hearts regained a pink colouration and
spontaneous rhythmic contraction with warming. In
10% of experiments, hearts were discarded due to signs
of ischaemia after cannulation and perfusion.
Perfused heart electrophysiological measurements
In the present experiments a paired (1 mm inter-pole
spacing) platinum stimulating electrode was placed on
the basal surface of the right ventricular epicardium.
Before experimental procedures, hearts were paced for
10 min at 8 Hz using 2 ms square-wave stimuli with
amplitudes set to three times the excitation threshold
(Grass S48 stimulator; Grass-Telefactor, Slough, UK).
Epicardial MAP recordings were obtained using a
MAP electrode (Linton Instruments, Harvard Appar-
atus) placed on the basal surface of the left ventricular
epicardium. The epicardial MAP electrode was gradu-
ally positioned until a gentle but stable contact pressure
was achieved. This resulted in a recording of MAP
signals. For endocardial recordings, a small access
window was created in the interventricular septum to
gain access to left ventricular endocardium (Casimiro
et al. 2001). A custom-made endocardial MAP elec-
trode constructed from two twisted strands of Teﬂon-
coated (0.25 mm diameter) silver wire (99.99% purity)
(Advent Research Materials, Oxford, UK) that had been
previously galvanically chlorided to eliminate DC off-
set, was positioned on to the left ventricular free wall
under a stable contact pressure until MAP signals were
achieved. MAPs were ampliﬁed, band-pass ﬁltered
(0.5 Hz to 1 kHz: Gould 2400S; Gould-Nicolet Tech-
nologies, Ilford, Essex, UK) and digitized (1401 plus
MKII; Cambridge Electronic Design, Cambridge, UK).
MAPs were extracted and analysed (Spike II version 4;
Cambridge Electronic Design) to derive the precise
duration of the digitized signals. The recordings were
deemed reproducible and, hence of an acceptable
standard for analysis if they had the following proper-
ties: a stable baseline, a rapid upstroke phase with
consistent amplitude, a smooth contoured repolariza-
tion phase and a stable duration [MAP duration at 90%
repolarization (APD90) was reproducible within 3 ms
under baseline conditions].
Experimental protocol
A standard pacing protocol (basic cycle length, BCL of
125 ms) that corresponded to physiological whole-
animal heart rates (Papadatos et al. 2002) was initiated
for periods of up to 20 min to measure APD at 50%,
70% and 90% repolarization. External pacing stimuli
were subsequently withdrawn from all preparations,
leading to a signiﬁcantly reduced, intrinsic heart rate
corresponding to a BCL of approximately 400 ms.
Reduced heart rates are a known risk factor for the
development of repolarization abnormalities such as
EADs and triggered beats that may underlie the
induction of VT (Roden & Hoffman 1985). Epicardial
MAPs were recorded for periods of up to 20 min from
isolated, perfused WT mouse hearts under intrinsic
pacing conditions. Following this, PES of the heart was
carried out using an adaptation of the corresponding
clinical techniques (Saumarez & Grace 2000, Balasu-
bramaniam et al. 2004). PES procedures began by
applying standard pacing stimuli at a BCL of 125 ms
for 25 s. Following this, a drive train of eight paced
beats (S1) again at a BCL of 125 ms preceded an
extrastimulus (S2) every ninth beat. S1S2 intervals
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progressively reduced by 1 ms with each nine beat cycle
until ventricular refractoriness was reached, at which
point the S2 stimulus elicited no MAP. Recordings were
subsequently repeated following a 20 min wash-in of a
reduced [K
+]o perfusate, of 3 mm in the absence and
presence of nifedipine (10 nm –1lm) or KN-93 (2 lm).
Repolarization time is obtained by the addition of
local activation times to APD. Activation time is the
time measured from the point of electrical stimulus to
the maximal amplitude of the action potential. How-
ever, in the present study, we only observed insigniﬁcant
changes in local activation time whether in the presence
of reduced [K
+]o alone or in combination with any of
the pharmacological agents used (data not shown). This
is in keeping with a previous study in which perfusion of
isolated rabbit hearts with amiodarone led to no
signiﬁcant increase or decrease in local activation times
(Kirchhof et al. 2003). With this in mind, the present
experiments quantiﬁed changes in transmural gradients
of repolarization by calculating the difference between
the epicardial APD90 and the endocardial APD90.
DAPD90 was calculated from the difference between
the mean endocardial and epicardial APD90 values,
giving positive results where the endocardial value
exceeded the epicardial value, and negative results
where the epicardial value was greater. An EAD was
deﬁned as a positive deﬂection that interrupted the
smooth repolarization phase of the AP. A triggered beat
was similarly described as a positive deﬂection in the
smooth repolarization phase of the action potential
whose amplitude approximately matched the amplitude
of the initial action potential. Arrhythmias were deﬁned
as ventricular tachyarrhythmias of more than ﬁve cycle
duration that were typically self-terminating.
Experimental solutions
Nifedipine (Sigma, Poole, UK) was initially prepared as
a1 m m stock solution in 96% ethanol. Subsequent
dilutions were made in the hypokalaemic buffer solu-
tion. All nifedipine solutions were kept wrapped in foil
to prevent light degradation. KN-93 (Tocris, Bristol,
UK) was initially prepared as a 10 mm stock solution
in DMSO, with further dilutions made in the hypoka-
laemic buffer solution. Final experimental solutions of
KN-93 contained no >0.02% DMSO, which had no
discernable effects upon MAP morphology in a series
of preliminary vehicle control experiments (data not
shown).
Statistical analysis
MAP data were initially imported into Microsoft excel.
All data are expressed as mean values   SEM.
Comparisons were made using anova (spss software)
with P-values <0.05 being considered signiﬁcant.
Results
Hypokalaemia is known to predispose to the induction
of a lethal ventricular arrhythmia termed TdP (Berthet
et al. 1999). Several lines of clinical and experimental
evidence implicate EADs and triggered activity in the
genesis of VT and TdP (Cosio et al. 1991, Shimizu et al.
1995, Aiba et al. 2005, Zhang et al. 2005). A recent
report has described an arrhythmic model in which
isolated murine hearts were perfused with a hypoka-
laemic physiological buffer solution of 3 mm [K
+]o: the
latter procedure results in the preferential prolongation
of epicardial over endocardial APD, to give preparations
with reduced left ventricular transmural gradients of
repolarization, andfrequent EADs.Thisyielded arrhyth-
mic preparationsshowing triggeredactivity andepisodes
of non-sustained VT that thereby fully recapitulated the
human clinical phenotype (Killeen et al. 2007).
We accordingly used this recently reported murine
model of arrhythmogenesis to resolve the relationship
between two macroscopic pathophysiological phenom-
ena, EADs and arrhythmogenic substrate of transmural
gradients of repolarization in the genesis of arrhythmias
at the whole heart level using two independent phar-
macological agents that affect Ca
2+ homeostasis. The
experiments recorded left ventricular epicardial and
endocardial monophasic action potentials (MAPs) from
isolated, perfused murine whole heart preparations
under hypokalaemic conditions and following perfusion
with nifedipine or KN-93.
Effects of nifedipine on EADs and spontaneous
arrhythmogenesis in intrinsically beating hypokalaemic
hearts
Following cannulation and perfusion the electrophysi-
ological parameters of MAP waveform morphology,
amplitude and duration reached a steady state within
10 min. MAP recordings in spontaneously beating
murine hearts subsequently remained highly reprodu-
cible throughout the duration of all experiments.
Bradycardia is a recognized risk factor for the develop-
ment of TdP (Roden & Hoffman 1985) and earlier
studies have reported a higher prevalence of EADs and
associated VT under bradycardic conditions (Milberg
et al. 2002, Fabritz et al. 2003, Killeen et al. 2007).
To increase the probability of EADs and their
associated triggered arrhythmic activity in murine
hearts, we recorded left ventricular epicardial and
endocardial MAPs from spontaneously beating isolated,
perfused murine hearts. Spontaneously beating hearts,
in the absence of extrinsic pacing, indeed displayed
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rations that were subjected to an extrinsic pacing
protocol [spontaneous ventricular CL 334   34 ms
(n ¼ 6) vs. 125 ms (n ¼ 6 paced preparations),
P < 0.05]. Perfusion with hypokalaemic solutions,
nifedipine or KN-93 had no effect upon intrinsic or
paced heart rates. Although we were not concerned
with the mechanical properties of the murine hearts, we
carefully monitored all hearts throughout all experi-
ments to ensure that they were beating continuously.
Spontaneously beating hearts perfused with normoka-
laemic physiological buffer solution in the absence of
any pharmacological agents elicited typical murine
ventricular MAPs lacking repolarization abnormalities
(Fig. 1a). However, following the transition to hypoka-
laemic conditions, spontaneously beating preparations
elicited prominent EADs and triggered beats that
preceded episodes of non-sustained VT (n ¼ 6; Fig. 1b).
EADs were observed in 62.1   7.7% of MAPs recorded
from all hypokalaemic hearts in a total recording time
in excess of 5 h duration (n ¼ 6). Episodes of sponta-
neous, non-sustained VT were associated with
19.1   5.9% of MAPs recorded from six hypokalaemic
preparations over a similar recording period exceeding
5 h duration. We proceeded to investigate the anti-
arrhythmic effects of a range of nifedipine concentra-
tions in spontaneously beating hypokalaemic hearts to
establish a correlation between EADs and arrhythmo-
genesis. The speciﬁc L-type Ca
2+ channel LTCC block-
ing properties of the dihydropyridine, nifedipine are
well established (Verheijck et al. 1999).
Perfusion of hypokalaemic hearts with 10 nm nif-
edipine, led to no signiﬁcant decrease in the incidence
of both EADs and episodes of VT. In six such separate
preparations, 66.9   15.7 and 10.8   6.3% of MAPs
were associated with EADs and episodes of VT,
respectively (P > 0.05). However, perfusion of hypoka-
laemic hearts with 100 nm nifedipine signiﬁcantly
halved the occurrence of EADs and VT to 28.3  
8.7 and 1.2   0.7%, respectively, in six separate
preparations (P < 0.05, n ¼ 6) (Fig. 1c). Finally, per-
fusion of spontaneously beating isolated hearts with a
hypokalaemic solution containing 1 lm nifedipine
elicited ventricular MAPs lacking any repolarization
abnormalities, such as EADs and triggered beats, in six
of six preparations (Fig. 1d). No episodes of sponta-
neous VT were recorded in any of the preparations
perfused with a hypokalaemic solution containing
1 lm nifedipine. Nifedipine (100 nm and 1 lm) exer-
ted its anti-arrhythmic effects in hypokalaemic murine
hearts immediately following perfusion. A signiﬁcant
suppression of EADs, triggered beats and VT occurred
within 30 s.
These data suggest that Ca
2+ inﬂux through LTCCs is
an important factor in the initiation of EADs and of
subsequent ventricular arrhythmias in the hypokalaemic
Figure 1 Representative left ventricular intrinsic epicardial monophasic action potential (MAP) recordings from isolated,
Langendorff-perfused mouse hearts under control conditions (a), and following perfusion with 3 mm [K
+]o hypokalaemic solutions
in the absence (b) and presence of 100 nm (c) and 1 lm (d) nifedipine. Perfusion of hypokalaemic hearts with 100 nm nifedipine
signiﬁcantly reduced the occurrence of early afterdepolarizations (EADs) and ventricular tachycardia (VT) in six of six hearts.
Perfusion with 1 lm nifedipine eliminated EADs and VT in six of six hearts.
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the feline ventricular wedge preparation pharmacolog-
ically made to model acquired LQT syndrome, in which
the phenylalkylamine LTCC blocker verapamil sup-
pressed EADs and VT (Aiba et al. 2005). Nifedipine
(100 nm) led to a signiﬁcant reduction in the occurrence
of EADs and VT. Furthermore, this concentration of
nifedipine closely matched the IC50 for nifedipine at the
LTCC previously reported at the single cell level (Shen
et al. 2000) and our recent ﬁndings in which we
calculated the IC50 for nifedipine in reducing EADs in
left ventricular MAPs in a genetically modiﬁed mouse
model of LQT 3 syndrome to be 79.3 nm (Thomas
et al. 2007a). At the highest concentration tested,
nifedipine (1 lm) eliminated all EADs and episodes of
VT in six of six hearts. We proceeded to investigate the
anti-arrhythmic effects of nifedipine upon provoked
ventricular arrhythmias in hypokalaemic hearts.
Effects of nifedipine on provoked arrhythmogenesis in
hypokalaemic hearts
Programmed electrical stimulation was next used to
determine the arrhythmic susceptibility produced by
extrasystolic stimulation of hypokalaemic isolated mu-
rine hearts perfused with graded concentrations of
nifedipine. In all preparations perfused with control
normokalaemic solutions PES failed to induce VT
(Fig. 2a). In contrast, closely coupled extra stimuli
successfully and reproducibly induced non-sustained
VT in six of six hypokalaemic preparations (Fig. 2b).
PES-induced VT persisted in hypokalaemic hearts
perfused with 10 and 100 nm nifedipine (Fig. 2c)
(n ¼ 12). However, PES failed to induce VT in any of
the six preparations perfused with 1 lm nifedipine
(Fig. 2d).
The present results using PES thus demonstrated that
only the highest concentration of nifedipine tested
(1 lm) protected hypokalaemic preparations against
provoked arrhythmogenesis, highlighting a contrast
between the PES results and recordings taken from
spontaneously beating hearts in which 100 nm nifedi-
pine exerted a signiﬁcant anti-arrhythmic effect, despite
the fact that identical preparations were used in both
sets of experiments. We therefore hypothesized that
these contrasting anti-arrhythmic effects of 100 nm
nifedipine may be due to the fact that 100 nm nifedipine
only eliminates the triggering factor (EAD) in sponta-
neously beating hearts, thus preventing VT in this
situation but not the arrhythmogenesis provoked by
imposed extrasystolic stimulation duing PES. Thus, PES
applies early S2 stimuli which may act as surrogate
EADs and initiate VT in conditions where an arrhyth-
mic substrate prevails. Such a hypothesis would then
require the highest concentration of nifedipine tested
(1 lm) to exert additional anti-arrhythmic effects
beyond suppression of EAD induction, such as altera-
tions in epicardial and endocardial APD which may
further reduce arrhythmic propensity in hypokalaemic
hearts by reducing arrhythmogenic substrate of the
transmural gradient of repolarization. Accordingly, we
studied the effects of the same concentrations of
nifedipine on epicardial and endocardial APD in control
and hypokalaemic hearts. Such measurements allow for
Figure 2 Programmed electrical stimulation (PES) of isolated, Langendorff-perfused mouse hearts under control conditions (a),
and following perfusion with 3 mm [K
+]o hypokalaemic solutions in the absence (b) and presence of 100 nm (c) and 1 lm (d)
nifedipine. Ventricular tachycardia (VT) persisted in six of six hypokalaemic hearts perfused with 10 and 100 nm. PES
repeatedly failed to induce VT under control conditions (6/6 hearts) and in hypokalaemic hearts perfused with 1 lm nifedipine
(6/6 hearts).
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gradient of repolarization which has been previously
correlated with arrhythmogenesis in recent reports
(Killeen et al. 2007, Stokoe et al. 2007a,b, Thomas
et al. 2007a,b).
Effect of nifedipine on action potential waveform under
hypokalaemic conditions
Epicardial and endocardial APD was measured under
steady state extrinsic pacing that corresponded to
whole-animal heart rates (Papadatos et al. 2002) to
eliminate any intrinsic variability in heart rate (Thomas
et al. 2007a,b). The experiments ﬁrst measured APD
from hearts perfused with normokalaemic and hypoka-
laemic solutions and in doing so conﬁrmed the recently
reported differential effects of hypokalaemia on murine
epicardial and endocardial APD and consequently the
net transmural gradient of repolarization in the left
ventricle (Killeen et al. 2007).
Contrasting APD measurements between the epicar-
dium and the endocardium were found in hypokalaemic
preparations. Hearts perfused with normokalaemic
physiological buffer solution in the absence of any
pharmacological agents elicited typical murine ventric-
ular epicardial and endocardial MAPs: a triangular
morphology and a smooth repolarization phase lacking
repolarization abnormalities such as EADs or triggered
beats (Fig. 3a). Endocardial APD90 was signiﬁcantly
greater than epicardial APD90 (50.0   1.4 vs.
38.4   2.4 ms, respectively, n ¼ 6, P < 0.05) giving a
corresponding DAPD90 of 11.6   3.0 ms (Figures 3a
and 4a). Perfusion of isolated hearts with 3 mm [K
+]o
preferentially prolonged epicardial compared with
endocardial APD at 90% repolarization time (APD90)
(Fig. 3b). Epicardial APD90 was increased from
38.4   2.4 to 66.1   3.4 ms and endocardial APD90
was increased to 50.0   1.4 to 62.6   3.6 ms
(P < 0.05, n ¼ 6) (Figs 3b and 4b). We documented
preferential epicardial vs. endocardial action potential
prolongation, insofar as epicardial APD90 exceeded
endocardial APD90 under hypokalaemic conditions.
These effects led to a dramatic reduction in the
transmural gradient of repolarization, DAPD90. Under
these hypokalaemic conditions, DAPD90 was signiﬁ-
cantly altered from 11.6   3.0 ms to )5.9   2.5 ms
(Figs 3a and 3b, 4a and b) (P < 0.05, n ¼ 6), conﬁrming
our earlier ﬁndings (Killeen et al. 2007).
We then proceeded to investigate the effects of
nifedipine at a range of concentrations (10 nm,
100 nm and 1 lm) upon hypokalaemia-induced action
potential prolongation at epicardial and endocardial left
ventricular sites. Perfusion of hypokalaemic hearts with
10 nm nifedipine did not signiﬁcantly alter epicardial or
endocardial APD90 (68.0   4.6 and 57.1   4.5 ms,
respectively; n ¼ 6, P > 0.05) (Figs 3c and 4c); similar
ﬁndings resulted from perfusion with 100 nm nifedipine
(67.6   0.3 and 68.0   4.6 ms, respectively; n ¼ 6,
P > 0.05) (Figs 3d and 4d). Consequently, the transmu-
ral gradient of repolarization was unaltered in the
presence of 10 and 100 nm nifedipine, with DAPD90
values, )10.9   3.7 and )0.47   4.4 ms, respectively,
which were not signiﬁcantly different to baseline
hypokalaemic values (n ¼ 12) (Fig. 4c and d). How-
ever, at the highest concentration tested, nifedipine
(1 lm) selectively abbreviated epicardial APD90 under
hypokalaemic conditions to 46.2   2.5 ms (P < 0.001),
whilst preserving endocardial APD90 (61.8   5 ms;
P > 0.05), resulting in the normalization of the trans-
mural gradient of repolarization, as reﬂected in a
Figure 3 Representative monophasic ac-
tion potential (MAP) recordings from the
left ventricular epicardium and endocar-
dium and transmural gradients of repo-
larization (endocardial APD90 minus
epicardial APD90) from isolated, Lange-
ndorff-perfused mouse hearts during a
standard pacing protocol at a basic cycle
length of 125 ms under control conditions
(a), and following perfusion with 3 mm
[K
+]o hypokalaemic solutions in the ab-
sence (b) and presence of 10 nm (c),
100 nm (d) and 1 lm (e) nifedipine.
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of murine ventricular repolarization in which endocar-
dial APD is greater than epicardial APD (Figs 3e and
4e). Under control normokalaemic conditions and
under hypokalaemic conditions in the presence of
1 lm nifedipine, DAPD90 and values were statistically
insigniﬁcant from one another (P > 0.05).
To determine if these effects of 1 lm nifedipine upon
epicardial APD, and hence the transmural gradient of
repolarization were dependant on the setting of hypo-
kalaemia, we perfused hearts with a normokalaemic
physiological solution containing 1 lm nifedipine. In six
separate preparations under normokalaemic conditions,
1 lm nifedipine did not signiﬁcantly alter epicardial or
endocardial APD from control values (42.2   2.6 and
50.8   3.0 ms, respectively, P > 0.05, n ¼ 6). Accord-
ingly in hearts perfused with 1 lm nifedipine under
normokalaemic conditions DAPD90 was not signiﬁ-
cantly altered from control normokalaemic values
(8.6   4.0 vs. 11.6   3.0 ms, respectively, P > 0.05,
n ¼ 6). These data suggest that the effects of nifedipine
upon epicardial APD are exclusive to a hypokalaemic
state.
Perfusion of hypokalaemic hearts with 1 lm nifedi-
pine restored DAPD90 to a positive value indistinguish-
able from control values, responses never recorded
following perfusion with 10 and 100 nm nifedipine in
which a negative DAPD90 value prevailed. Selective
abbreviation of epicardial over endocardial APD in
hypokalaemic hearts by 1 lm nifedipine accounted for
this phenomenon and supported earlier ﬁndings using
verapamil in the feline ventricular wedge preparation
made to model acquired LQT syndrome (Aiba et al.
2005). We have previously correlated negative values of
DAPD90 with ventricular arrhythmias in a range of
murine models of arrhythmogenesis including hypo-
kalaemia-induced VT (Killeen et al. 2007) and genetic-
ally modiﬁed models of LQT3 (Stokoe et al. 2007a,b,
Thomas et al. 2007a) and LQT5 (Thomas et al. 2007b).
In keeping with these studies, perfusion of hypokalaem-
ic hearts with 1 lm nifedipine restored DAPD90 to
positive values and was associated with a marked
reduction in arrhythmogenecity under both spontane-
ously beating and PES protocols. These data suggest
that arrhythmic substrate of DAPD90 is only affected by
1 lm nifedipine.
Effects of alteration of calcium homeostasis through
inhibition of calmodulin kinase type II
Calmodulin kinase type II (CaMKII) has been shown to
be a proarrhythmic signalling molecule in an experi-
mental model of drug-induced LQT syndrome (Wu
et al. 1999). We accordingly assessed for the ﬁrst time
the effects of acute pharmacological inhibition of
CaMKII with KN-93, a direct inhibitor of CaMKII
(Fleming et al. 1998) in establishing a causal relation-
ship between EADs and arrhythmic substrate in the
initiation of arrhythmias at the whole heart level for the
ﬁrst time in any cardiac preparation.
The concentration of KN-93 used in the present study
was based upon a careful consideration of the literature.
Previously, at the single cell level, CaMKII inhibitors
have been used at concentrations ranging from 1 lm
(Wu et al. 2002) to 20 lm (Wu et al. 1999). An
additional six hypokalaemic hearts were perfused with
KN-93 (2 lm). Firstly, under hypokalaemic conditions,
KN-93 did not signiﬁcantly alter epicardial or endocar-
dial APD90 (Fig. 5a and b) (68.3   2.7 and
62.9   2.0 ms, respectively; P > 0.05, n ¼ 6). Accord-
ingly, the transmural gradient of repolarization, reﬂec-
ted in DAPD90, was not signiﬁcantly different to values
under hypokalaemic conditions (Fig. 5a and b)
()5.3   2.8 vs. )5.9   2.5 ms, respectively, P > 0.05,
n ¼ 6).
Secondly, spontaneously beating hypokalaemic hearts
perfused with KN-93 elicited a signiﬁcantly reduced
frequency of both EADs and episodes of VT. In a total
of six separate preparations throughout a total record-
ing time in excess of 5 h duration, the percentage of
Figure 4 Steady-state epicardial and
endocardial APD measured at 90% re-
polarization (APD90), and DAPD90 values
(white, grey and black columns, respect-
ively) under control conditions (a), and
following perfusion with 3 mm [K
+]o
hypokalaemic solutions in the absence (b)
and presence of 10 nm (c), 100 nm (d)
and 1 lm (e) nifedipine.
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from 62.1   7.7% under hypokalaemic conditions to
29.6   8.9% following perfusion with KN-93
(P < 0.05, n ¼ 6) (Fig. 6a). Similarly, the percentage
of MAPs associated with episodes of non-sustained VT
signiﬁcantly fell from 19.1   5.9% under hypokalaem-
ic conditions, to 1.7   1.1% in the presence of KN-93
over a similar length of recording time in six separate
preparations (P < 0.05, n ¼ 6).
Finally, the anti-arrhythmic efﬁcacy of KN-93 in the
setting of hypokalaemia was quantiﬁed by applying PES
procedures. PES induced VT in six of six hypokalaemic
preparations perfused with KN-93 (Fig. 6b). Whereas
2 lm KN-93 signiﬁcantly reduced arrhythmogenecity in
spontaneously beating hypokalaemic hearts, it failed to
protect against provoked arrhythmogenesis under PES
protocols in six of six hypokalaemic hearts. KN-93 did
not have any effect upon epicardial or endocardial APD,
and the resulting DAPD90 value was not signiﬁcantly
different compared with baseline hypokalaemic hearts.
Thus PES applies early S2 stimuli, acting as surrogate
EADs, upon an arrhythmogenic substrate of DAPD90
which induced VT. Collectively these ﬁndings demon-
strate for the ﬁrst time the pharmacological separation
of EADs and altered transmural gradients of repolari-
zation in a whole heart model of arrhythmogenesis
through the application of two independent agents each
with different molecular targets.
Discussion
Hypokalaemia, a common medical condition, is known
to have severe consequences in particular clinical
situations (Steiness & Olesen 1976) and is a known
risk factor for the development of TdP and related,
potentially lethal arrhythmias (Berthet et al. 1999).
EADs and changes in the ventricular transmural gradi-
ent of repolarization are known key contributors to the
pathogenesis of ventricular arrhythmias (Milberg et al.
2005, Thomas et al. 2007a,b, Vandenberg et al., 2001).
Figure 5 Steady-state epicardial and
endocardial APD measured at 90% re-
polarization (APD90), and DAPD90 values
(white, grey and black columns, respect-
ively) (a) and representative monophasic
action potential (MAP) recordings from
the left ventricular epicardium and endo-
cardium and transmural gradient of re-
polarization (b) from isolated,
Langendorff-perfused wild-type (WT)
mouse hearts perfused with 3 mm [K
+]o
hypokalaemic solutions in the presence of
2 lm KN-93.
Figure 6 Representative left ventricular intrinsic epicardial
monophasic action potential (MAP) recordings (a), and pro-
grammed electrical stimulation (PES) (b) of mouse hearts per-
fused with 3 mm [K
+]o hypokalaemic solutions in the presence
of 2 lm KN-93. KN-93 reduced the occurrence of early
afterdepolarizations (EADs), triggered beats and ventricular
tachycardia (VT) in spontaneously beating hearts but failed to
protect against provoked arrhythmogenesis during PES in six
of six hearts.
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model of arrhythmogenesis (Killeen et al. 2007) to
study for the ﬁrst time the precise pathophysiological
causal relationship between EADs and transmural
gradients of repolarization in the development of
ventricular arrhythmias at the whole heart level using
two independent modiﬁers of Ca
2+ homeostasis.
The present study used the contact MAP electrode
technique (Franz et al., 1999). It was an absolute
requirement of our study for the myocardium to be
intact, and working under physiological conditions.
The use of any other technique to measure APs would
have required the dissection and preparation of the
myocardium into isolated tissue preparations or iso-
lation of the myocardium into single cells. Such
procedures remove re-entry mechanisms, intercellular
coupling and dispersions of repolarization present in the
whole heart, which are all considered to play a crucial
role in arrhythmogenesis. Transmembrane APs (TAPs)
require impalement of cardiac tissue with a sharp glass
microelectrode, which negates their use in the recording
of in situ waveforms from the beating heart. MAPs are
extracellularly recorded waveforms that have been
previously shown to accurately reproduce waveform
morphology, amplitude and repolarization times of
transmembrane action potentials (TAPs) from the
mouse heart with a high level of accuracy (Knollmann
et al. 2001). The durations and transmural dispersion
repolarization times we report in the present study
under control conditions and following perfusion with
hypokalaemic solutions in the absence and presence
of nifedipine and KN-93 are statistically signiﬁcant
increases or decreases as opposed to measurements of
absolute values, and correspond to previous measure-
ments in earlier studies (Fabritz et al. 2003, Killeen
et al. 2007). These data thus represent highly accurate
and reproducible changes that have been recorded from
the ventricular surfaces of the intact, beating mouse
heart over a considerable length of time demonstrating
a high level of stability of our MAP recordings.
Firstly, the present study has shown that nifedipine
eliminated EADs and VT in spontaneously beating
hypokalaemic hearts in a concentration-dependant
fashion. Spontaneously beating hearts proved a partic-
ularly appropriate system for such study, as their
relatively reduced heart rates provoked preparations
with an increased propensity for the development of
repolarization abnormalities such as EADs and trig-
gered beats, which preceded episodes of VT in the
setting of hypokalaemia (Killeen et al. 2007). Further-
more, these ﬁndings at the whole heart level correlate
with earlier cellular studies which implicated ICa,L as the
necessary depolarizing charge carrier for the induction
of EADs at slow stimulation rates (Damiano & Rosen
1984, Zeng & Rudy 1995).
The proposed mechanism for EADs in the setting of
action potential prolongation is the elevation of
intracellular Ca
2+ concentration through the increased
opening of LTCCs that occurs secondary to action
potential prolongation, demonstrated in isolated car-
diac myocytes. Impaired cardiac repolarization and
critical lengthening of APD leads to a lengthening of the
cardiac action potential plateau within a critical voltage
‘window’ range enabling reactivation of LTCCs, and a
subsequent secondary release of calcium from the
sarcoplasmic reticulum (SR) leading to an aftercontrac-
tion (January & Riddle 1989, Ming et al. 1994,
Viswanathan et al. 1999). Accordingly, reductions in
[K
+]o have been associated with action potential pro-
longation and an appearance of EADs and arrhythm-
ogenesis (Killeen et al. 2007).
Whereas 10 nm nifedipine had no effects upon the
frequency of unprovoked EADs and VT in spontane-
ously beating hypokalaemic hearts, 100 nm nifedipine
signiﬁcantly halved the occurrence of both EADs and
subsequent VT in six of six preparations. Finally,
perfusion of hypokalaemic hearts with 1 lm nifedipine
eliminated EADs in six of six hearts and abolished VT
in all preparations. This ﬁnding is in agreement with our
recent study in which nifedipine reduced EADs in
spontaneously beating mouse hearts genetically modi-
ﬁed to model human LQT3 syndrome with an EC50 of
79.3 nm (Thomas et al. 2007a).
Secondly, in contrast to the above assessments of
spontaneous arrhythmogenecity, we assessed the ten-
dency to arrhythmogenesis speciﬁcally provoked by
imposed extrasystolic stimulation, and the effect upon
this of nifedipine in the hypokalaemic heart at a range
of concentrations using an established method of PES.
Under control, normokalaemic conditions, VT was
never induced in preparations during PES protocols.
However, PES successfully induced VT in all hypoka-
laemic hearts, in addition to those perfused with 10 nm
nifedipine. Similarly, 100 nm nifedipine failed to pre-
vent provoked ventricular arrhythmogenesis in all six
preparations, in contrast to its anti-arrhythmic effects
recorded from spontaneously beating hypokalaemic
hearts. However, PES failed to induce VT in any
hypokalaemic preparation perfused with 1 lm nifedi-
pine.
Thirdly, the above contrast suggests that 1 lm
nifedipine may be exerting additional effects, beyond
suppression of EADs, which could also account for its
anti-arrhythmic efﬁcacy in the hypokalaemic heart. We
accordingly sought to investigate the basis of these
differential efﬁcacies shown by nifedipine by measuring
changes in the transmural gradient of repolarization in
response to perfusion with increasing concentrations of
nifedipine. These explorations were prompted by earlier
reports that associated changes in the transmural
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range of cardiac models (Milberg et al. 2005, Killeen
et al. 2007, Stokoe et al. 2007a,b, Thomas et al.
2007a,b). The present experiments have shown that
administration of 1 lm nifedipine to hypokalaemic
hearts led to selective attenuation of epicardial as
opposed to endocardial APD90 in hypokalaemic hearts.
This restored the DAPD90 in hypokalaemic hearts to
values seen in non-arrhythmogenic, untreated norm-
okalaemic hearts. This ﬁnding is in agreement with our
recent study using arrhythmogenic mice modelling
human LQT5 syndrome through targeted disruption
of KCNE1, in which 1 lm nifedipine selectively reduced
epicardial APD, whilst having no similar affect upon
endocardial APD (Thomas et al. 2007b). In the present
study, such ﬁndings were not recorded following
perfusion with lower concentrations of nifedipine.
Additionally, Aiba et al. (2005) showed that verapamil
preferentially abbreviated epicardial compared with
endocardial APD, leading to a normalization in the
transmural gradient of repolarization alongside the
suppression of EADs, triggered activity and TdP in the
perfused feline left ventricle made to model subclinical
dysfunction of IKs alongside drug-induced LQTS. These
effects of nifedipine upon epicardial APD appeared to
be exclusive to the pathophysiological state of hypo-
kalaemia. Thus under normokalaemic conditions the
highest concentration of nifedipine had no effects upon
epicardial and endocardial APD and hence DAPD90 in
wild-type hearts, in keeping with our recent ﬁndings
(Thomas et al. 2007b). In the present study, we report
for the ﬁrst time that epicardial APD is reduced by the
LTCC blocker nifedipine under hypokalaemic condi-
tions at micromolar concentrations.
At the whole heart level, we have previously shown
that nifedipine (1 lm) eliminated episodes of VT in
genetically modiﬁed mouse models of LQT3 and LQT5
generated through targeted disruption of SCN5a and
KCNE1, respectively (Thomas et al. 2007a,b) through
blockade of the LTCC. However, nifedipine may also
exert its anti-arrhythmic efﬁcacy through reduced SR
calcium release secondary to longer inhibition of
calcium inﬂux through LTCCs. Indeed, we have previ-
ously shown that pre-treatment of isolated murine
ventricular myocytes with nifedipine reduces electrically
evoked calcium transients, indicative of a reduction in
SR calcium release (Balasubramaniam et al. 2004).
Nevertheless due to the rapid onset of action of
nifedipine in the hypokalaemic murine heart, we believe
that acute inhibition of the L-type calcium channel by
nifedipine predominantly accounts for its anti-arrhyth-
mic efﬁcacy. In the present study, we were concerned
primarily with the elucidation of the electrical abnor-
malities in the intact heart that underlie arrhythmo-
genesis – EADs and altered transmural gradients of
repolarization. We were not concerned with the con-
tractile or mechanical properties of the heart. However,
a reduction in inotropy and hence cardiac output
through LTCC blockade may also account for the
anti-arrhythmic effects of nifedipine. However, a previ-
ous study has determined that inhibition of EADs and
VT by nifedipine in the rabbit heart signiﬁcantly
preceded any discernable decreases in left ventricular
developed pressure (LVDP) (Anderson et al. 1998).
Taken together these ﬁndings support the notion that
the anti-arrhythmic effects induced through pharmaco-
logical inhibition of the LTCC by nifedipine occur
independently of signiﬁcant effects upon the mechanical
functions of the isolated murine heart.
We used maximum nifedipine concentrations of 1 lm
in the present experiments; concentrations between 1
and 2 lm sufﬁce to substantially reduce Ca
2+ transients
and ICa,L in isolated murine and rabbit myocytes
(Balasubramaniam et al. 2004). Furthermore, nifedi-
pine concentrations as high as 5 lm have no effects
upon ICa,T, INa, IK and If (Verheijck et al. 1999, Gao
et al. 2005). Additionally in isolated rodent myocytes,
the inwardly rectifying current (IK1), the rapidly acti-
vating delayed-rectiﬁer current (IKr) and slowly activa-
ting delayed-rectiﬁer current (IKs) are unaffected by
nifedipine concentrations £10 lm, although individual
currents were affected by nifedipine concentrations of
260, 275 and 360 lm respectively (Zhabyeyev et al.
2004). Whatever the underlying mechanism governing
the anti-arrhythmic efﬁcacy of nifedipine, these results
using a range of concentrations of nifedipine empirically
demonstrate for the ﬁrst time the pharmacological
separation of EADs from arrhythmic substrate using a
modiﬁer of Ca
2+ homeostasis in a whole heart model of
arrhythmogenesis. We thus implicate both EADs and
arrhythmic substrate in the induction of arrhythmias at
the whole heart level.
Finally, we corroborated these ﬁndings with nifedi-
pine using an independent pharmacological agent
which also affects Ca
2+ homeostasis through inhibi-
tion of CaMKII, KN-93. We report that KN-93
indeed leads to a signiﬁcant reduction of EADs,
triggered beats and episodes of VT in the spontane-
ously beating hypokalaemic heart. In the present
study, KN-93 signiﬁcantly reduced the frequency of
EADs and episodes of VT in spontaneously beating
hypokalaemic hearts, yet failed to protect against
provoked arrhythmogenesis in the PES studies. Fur-
thermore, KN-93 failed to signiﬁcantly alter epicardial
or endocardial APD90 under hypokalaemic conditions,
preserving arrhythmogenic substrate of DAPD90.
Thus, PES induced early stimuli, acting as surrogate
EADs, imposed upon an arrhythmogenic substrate of
DAPD90 to induce VT. To the best of our knowledge
this is the ﬁrst report documenting these differential
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cardiac preparation.
Calmodulin kinase type II has emerged as an
important arrhythmogenic signalling molecule in the
setting of LQT syndrome (Wu et al. 1999), cardiac
hypertrophy (Wu et al. 2002) and cardiomyopathy
(Khoo et al. 2005). Following initial activation by
increased [Ca
2+]i, CaMKII activity becomes partly
Ca
2+-independent, through a mechanism involving
intersubunit autophosphorylation (Braun & Schulman
1995). In arrhythmogenic rabbit hearts Anderson et al.
(1998) measured a signiﬁcant increase in Ca
2+-inde-
pendent CaMKII activity compared with control hearts.
Pre-treatment with KN-93 abolished arrhythmogenecity
and corresponding increases in Ca
2+-independent CaM-
KII activity (Anderson et al. 1998). These data suggest
that CaMKII activity, although dependant upon [Ca
2+]i
for initial activation, transitions into a Ca
2+-independ-
ent state and plays an important role in EAD induction
and subsequent arrhythmogenesis.
Studies have ascribed the anti-arrhythmic effects of
acute pharmacological inhibition of CaMKII to de-
creased activity of LTCCs. A study by Wu et al. (2004)
demonstrated that calmodulin kinase is functionally
targeted to and is a critical regulator of the LTCC.
Additionally in genetically modiﬁed mice modelling
cardiac hypertrophy through increased CaMKII acti-
vity, Wu et al. (2002) showed that transgenic ventric-
ular myocytes had an increased LTCC open probability,
compared with WT myocytes, corresponding to a high
frequency of EADs and arrhythmias in the transgenic
mice. Pharmacological inhibition of CaMKII reduced
LTCC open probability in transgenic myocytes to levels
found in WT myocytes (Wu et al. 2002). Thus,
pharmacological inhibition of CaMKII is an effective
measure to target the LTCC and to exert potent anti-
arrhythmogenic effects.
Additionally, CaMKII has also been shown to affect
other ion channels and intracellular targets. The
sodium–calcium exchanger (NCX) is regulated by
CaMKII activity (Wu et al. 1999) which can cause
arrhythmogenic inward currents which may give rise to
EADs. However, previous studies have shown that
selective NCX inhibition does not preclude the induc-
tion of EADs and arrhythmias in a range of arrhythm-
ogenic cardiac models (Shinada et al. 2005, Zhang
et al. 2005). It was recently shown that CaMKII may
reduce Na
+ channel availability at high heart rates and
increase late Na
+ current in transgenic mice over
expressing CaMKII (Wagner et al. 2006). Reduced
Na
+ channel availability would be expected to reduce
APD, whereas increased late Na
+ current would be
expected to increase APD. We observed neither an
increase nor a decrease in APD in hypokalaemic hearts
treated with the CaMKII inhibitor KN-93, precluding
an effect of KN-93 on Na
+ channels in the present
study.
A recent study has also suggested that inhibition of
CaMKII activity may increase repolarizing K
+ currents,
in particular Ito (Li et al. 2006). We consider these
actions unlikely in the present study for the following
reasons. Chronic, genetic inhibition of CaMKII was
necessary for the observed changes in Ito, acute phar-
macological inhibition of CaMKII had no effect upon
repolarizing K
+ currents (Li et al. 2006). Furthermore,
acute inhibition of CaMKII by KN-93 did not signiﬁ-
cantly affect epicardial or endocardial APD in the
present study. KN-93 has also recently been shown to
block K
+ channels and reduce repolarizing K
+ currents
(Rezazadeh et al. 2006). Inhibition of K
+ channels by
KN-93 would be expected to prolong the cardiac AP,
which may potentially negate any beneﬁcial anti-
arrhythmic effects. Indeed, Kirchhof et al. (2004)
showed that KN-93 prolonged epicardial APD in mice
under control, normokalaemic conditions. However, in
the present study, we consider the blocking effects
KN-93 upon K
+ channels unlikely for several reasons.
Firstly, KN-93 failed to signiﬁcantly affect epicardial or
endocardial APD in the hypokalaemic heart. Secondly, if
KN-93 did block K
+ channels and prolong APD, one
would expect an increased level of EADs and episodes of
VT, which we did not observe. These ﬁndings exclude an
effect of KN-93 upon repolarizing K
+ channels in the
present study.
Sarcoplasmic and endoplasmic reticulum ATP-ase
(SERCA) activity can also be affected by CaMKII via
phosphorylation of phospholamban (Tada et al. 1982).
Thus, KN-93 inhibition of CaMKII inhibits the phos-
phorylation of phospholamban and was shown to
signiﬁcantly decrease SR Ca
2+ content (Kim et al.
2000). Additionally, previous studies have documented
either increased (Guo et al. 2006) or decreased (Wu
et al. 2002) SR Ca
2+ release associated with CaMKII
activity. Guo et al. (2006) demonstrated that endo-
genousCaMKIIactivitycanphosphorylatetheryanodine
receptor (RyR2), leading to an increase in channel
opening and increased SR Ca
2+ release events. Inhibition
of CaMKII by KN-93 may thus reduce SR Ca
2+ content
and reduce RyR2 channel opening, effects which may
also contribute to its anti-arrhythmic efﬁcacy. Agents
which affect Ca
2+ homeostasis may alter myocardial
inotropy and cardiac output, which may also be an anti-
arrhythmogenic mechanism of action. However, a study
by Valverde et al. (2004) concluded that inhibition of
CaMKII by KN-93 did not play a signiﬁcant role in
mechanisms governing myocardial contraction and
relaxation in the isolated, perfused rat heart.
Nevertheless, we used KN-93 as a tool which affects
Ca
2+ homeostasis to empirically separate out EADs
from arrhythmogenic substrate in the hypokalaemic
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observed using nifedipine. Whatever the underlying
anti-arrhythmogenic mechanism of KN-93, we have
demonstrated that acute inhibition of CaMKII reduces
arrhythmogenecity in spontaneously beating hearts by
removing the trigger for the arrhythmia, the EAD. The
failure of KN-93 to restore DAPD90, maintains the
arrhythmic substrate and leads to the induction of
arrhythmias in provoked studies using PES.
In conclusion, we report that the empirical use of two
independent pharmacological agents that modify Ca
2+
homeostasis, nifedipine and KN-93, permit the separ-
ation of two of the previously accepted predominantly
causative factors for arrhythmogenesis: EADs and
arrhythmic substrate. These ﬁndings were demonstrated
in a recently reported whole heart model of arrhythm-
ogenesis that presents with action potential prolonga-
tion, EADs, triggered beats and VT, and which fully
recapitulates the human clinical phenotype (Killeen
et al. 2007). To the best of our knowledge these ﬁndings
in the present study have not been reported in any other
mammalian cardiac preparation. KN-93 and mid-range
concentrations of nifedipine eliminated EADs but failed
to alter DAPD90, actions which abolished spontaneously
occurring arrhythmias but preserved provoked arrhyth-
mias using PES. Collectively, these ﬁndings clarify the
causal relationship between EADs and arrhythmic
substrate in the induction of arrhythmias at the whole
heart level.
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